ClinicalTrials.gg
CompletedNCT03730012Updated Nov 29, 2024Results posted

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

A Phase 1/2 interventional study of gilteritinib and atezolizumab in Acute Myeloid Leukemia (AML) and Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, sponsored by Astellas Pharma Global Development, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute — 13 open to participants now, 15 under way, 6 of them phase 3. gilteritinib · Leukemia, Myeloid, Acute.

Enrollment
28th of 31
11 · median 97
Started
2019
with 3 others
Phase 1/2
8 of 31
2 open now
Registered
13th of 31
by date
Lead sponsor
10 of 31
Astellas Pharma Global Development, Inc.

Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, this one is the 28th largest by enrollment, is one of 4 that started in 2019, is one of 8 in phase 1/2, and was the 13th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

13 of the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About gilteritinib

gilteritinib: first FDA approval 2018 (XOSPATA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study was to determine the safety and tolerability of gilteritinib given in combination with atezolizumab in participants with relapsed or treatment refractory FMS-like tyrosine kinase 3 (FLT3) mutated AML and to determine the composite complete remission (CRc) rate for participants who either discontinued the study or completed 2 cycles of gilteritinib given in combination with atezolizumab.

This study also evaluated pharmacokinetics (PK), response to treatment, remission and survival. Adverse events (AEs), clinical laboratory results, vital signs, electrocardiograms (ECGs), and Eastern Cooperative Oncology Group (ECOG) performance status scores were also assessed.

Read the detailed description

This study was planned to have 2 phases:

Phase 1:

The phase 1 portion of this study was to establish the recommended phase 2 dose (RP2D) of gilteritinib given in combination with atezolizumab.

Phase 2:

The phase 2 portion of the study was to treat participants with gilteritinib and atezolizumab at the RP2D and was to be enrolled in two stages. The first stage was to evaluate the remission rate and if a minimum rate was to be achieved, a second stage of enrollment was to be continued.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

Keywords

  • AML
  • gilteritinib
  • ASP2215
  • Acute Myeloid Leukemia
  • FLT3
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is considered an adult according to local regulation at the time of signing form (ICF).
  • Subject has defined AML by the World Health Organization (WHO) criteria (2017) and fulfills one of the following:

    • to at least 1 cycle of induction chemotherapy
    • Relapsed after achieving remission with a prior therapy
  • Subject is positive for FLT3 mutation in bone marrow or blood after completion of the subject's last interventional treatment.
  • Subject has an (ECOG) performance status ≤ 2 at screening.
  • Subject must meet the following criteria as indicated on the clinical laboratory tests:

    • Serum (AST) and Alanine Aminotransferease (ALT) ≤ 2.5 x (ULN)
    • Serum total (TBL) ≤ 1.5 x ULN
    • Serum creatinine ≤ 1.5 x ULN or an estimated of > 50 mL/min as calculated by the Modification of Diet in Renal Disease equation.
  • Subject is suitable for oral administration of study drug.
  • A female subject is eligible to participate if she is not pregnant and at least one of the following conditions applies:

    • Not a woman of (WOCBP) OR
    • WOCBP who agrees to follow the guidance throughout the treatment period and for at least 180 days after the final study drug administration.
  • Female subject must agree not to breastfeed starting at screening and throughout the study period, and for at least 180 days after the final study drug administration.
  • Female subject must not donate ova starting at screening and throughout the study period, and for at least 180 days after the final study drug administration.
  • A male subject must not donate sperm starting at screening and throughout the treatment period, and for at least 120 days after the final study drug administration.
  • A male subject with female partner(s) of child-bearing potential must agree to use contraception during the treatment period, and for at least 120 days after the final study drug administration.
  • Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the treatment period, and for 120 days after the final study drug administration.
  • Subject agrees not to participate in another study while on treatment.

Exclusion criteria

Exclusion Criteria:

  • Subject was diagnosed as acute promyelocytic leukemia.
  • Subject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
  • Subject has AML secondary to prior chemotherapy for other neoplasms (except for myelodysplastic syndrome).
  • Subject has clinically active central nervous system leukemia.
  • Subject has uncontrolled or significant cardiovascular disease, including:

    • A myocardial infarction within 12 months
    • Uncontrolled angina within 6 months
    • History of ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, torsades de pointes) or any history of arrhythmia
    • Uncontrolled hypertension
  • Subject has baseline that is ≥ 45%.
  • Subject has mean triplicate Fridericia- interval (QTcF) > 450 ms at Screening based on central reading.
  • Subject has congenital or acquired Long QT Syndrome at screening.
  • Subject has hypokalemia and/or hypomagnesemia at screening.
  • Subject has been diagnosed with another that requires concurrent treatment or hepatic malignancy regardless of the need for treatment.
  • Subject has clinically significant coagulation abnormality unless secondary to AML.
  • Subject is receiving or plans to receive concomitant chemotherapy or immunotherapy.
  • Subject has had major surgery within 4 weeks prior to the first study dose.
  • Subject has radiation therapy within 4 weeks prior to the first study dose.
  • Subject requires treatment with concomitant drugs that are strong inducers of Cytochrome P450 ().
  • Subject has known pulmonary disease with diffusion capacity of lung for carbon monoxide ≤ 65%, (FEV1) ≤ 65%, dyspnea at rest or requiring oxygen or any pleural neoplasm.
  • Subject with systemic fungal, bacterial, viral or other uncontrolled infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment. Subject needs to be off pressors and have negative blood cultures for 48 hours.
  • Subject has not recovered from any prior therapy related toxicities.
  • Subject is known to have infection.
  • Subject has active or C or other active hepatic disorder.
  • Subject has previously been treated with gilteritinib, quizartinib or crenolanib (will only apply to subjects enrolled in the phase 2 portion of the study).
  • Subject has active clinically significant (GVHD) or is on treatment with systemic for GVHD.
  • Subject has after hematopoietic stem cell transplant (HCST).
  • Subject has an active disorder that makes the subject unsuitable for study treatment or participation.
  • Subject has any condition that makes the subject unsuitable for study participation.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Gilteritinib 120 mg + Atezolizumab 420 mg

    Participants received 120 milligrams (mg) giltertinib (3 tablets of 40 mg) orally, once a day in continuous 28-day cycles in combination with atezolizumab 420 mg adminstered by intravenous infusion (over 60 minutes) once every 2 weeks of 28-day cycle until the participant no longer received clinical benefit from therapy, unacceptable toxicity occurred or the participant met a treatment discontinuation criterion (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab).

    Drug: gilteritinib · Drug: atezolizumab

  • Experimental
    Gilteritinib 120 mg + Atezolizumab 840 mg

    Participants received 120 mg giltertinib (3 tablets of 40 mg) orally, once a day in continuous 28-day cycles in combination with atezolizumab 840 mg administered by intravenous infusion (over 60 minutes) once every 2 weeks of 28-day cycle until the participant no longer received clinical benefit from therapy, unacceptable toxicity occurred or the participant met a treatment discontinuation criterion (Maximum treatment duration was 126 days for gilteritinib and 70 days for atezolizumab).

    Drug: gilteritinib · Drug: atezolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLT)

    DLTs were defined as: * Confirmed Hy's Law case * Any Grade ≥ 3 non-hematologic or extramedullary toxicity with the following exceptions: * Anorexia or fatigue * Grade 3 nausea and/or vomiting if participant did not require tube feeding or total parenteral nutrition, or diarrhea if the events did not require or prolong hospitalization that could be managed to grade ≤ 2 with standard antiemetic or antidiarrheal medications used at prescribed dose within 7 days of onset. * Grade 3 mucositis that resolved to Grade ≤ 2 within 7 days of onset * Grade 3 fever with neutropenia, with or without infection * Grade 3 infection * Grade 3 infusion-related toxicity, if successfully managed and resolved within 72 hours.

    Time frame: Day 1 up to 28 days

Secondary outcomes

  1. Composite Complete Remission (CRc) Rate

    CRc was defined as rate of all complete and incomplete remissions i.e. CR + CR with incomplete platelet recovery (CRp) + CR with incomplete hematological recover (CRi). Participants were classified as: CR if they achieved morphologic leukemia-free state \& their bone marrow was regenerating normal hematopoietic cells. If they had absolute neutrophil count (ANC) \> 1 × 10\^9/L, platelet count ≥ 100 × 10\^9/L, normal marrow differential \< 5% blasts, \& were red blood cell (RBC) and platelet transfusion independent (defined as 1 week without RBC transfusion and platelet transfusion prior to disease assessment). There was also no evidence of extramedullary leukemia. CRp if they achieved CR with incomplete platelet recovery (\< 100 × 10\^9/L). CRi if they achieved CR with incomplete hematological recovery with residual neutropenia \< 1 × 10\^9/L, with or without complete platelet recovery. RBC and platelet transfusion independence was not required. Percentage of participants with CRc was reported.

    Time frame: From the date of first dose up to end of treatment (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)

  2. Plasma Ctrough Concentration of Gilteritinib

    Plasma Ctrough concentrations of gilteritinib was reported. One cycle = 28 days. C= cycle, D=day

    Time frame: Pre-dose on C1D1, C1D8, C1D15, C2D1,C2D15, C3D1, C3D15, C4D1, C4D15, C5D1, C5D15, C6D1, C6D15

  3. Complete Remission (CR) Rate

    Participants were classified as CR if they achieved a morphologic leukemia-free state and their bone marrow was regenerating normal hematopoietic cells. In addition, these participants had ANC \> 1 × 10\^9/L, platelet count ≥ 100 × 10\^9/L, normal marrow differential with \< 5% blasts, and were RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion prior to disease assessment). There was also no evidence of extramedullary leukemia. CR rate was defined as the number of participants with CR divided by the number of participants in the analysis population. Percentage of participants with CR was reported.

    Time frame: From the date of first dose up to end of treatment (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)

  4. Complete Remission With Partial Hematologic Recovery (CRh) Rate

    Participants were classified as CRh if they achieved CR with ANC level of \> 0.5 × 10\^9/L and platelet count of \> 50 × 10\^9/L. CRh rate was defined as the number of participants with CRh divided by the number of participants in the analysis population. Participants were classified as CR if they achieved a morphologic leukemia-free state and their bone marrow was regenerating normal hematopoietic cells. In addition, these participants had ANC \> 1 × 10\^9/L, platelet count ≥ 100 × 10\^9/L, normal marrow differential with \< 5% blasts, and were RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion prior to disease assessment). There was also no evidence of extramedullary leukemia. Percentage of participants with CRh was reported.

    Time frame: From the date of first dose up to end of treatment (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)

  5. Best Response Rate

    Best response was defined as the best-measured response (CR, CRp, CRi or PR) post-treatment. Best response rate was defined as the number of participants with CR or CRp or CRi or PR divided by the number of participants in the analysis population (i.e., CR+ CRp + CRi + PR). Participants with unknown or missing response, or who provide no information on response at the end of study will be treated as non-responders and will be included in the denominator when calculating rates. CR, CRp and CRi were described in outcome measure 2#. Participants were classified as PR if their bone marrow was regenerating normal hematopoietic cells with evidence of peripheral recovery with no (or only a few regenerating) circulating blasts and a decrease of at least 50% in the percentage of blasts in the bone marrow aspirate/biopsy, with the total marrow blasts between 5% and 25%. Percentage of participants with best response was reported.

    Time frame: From the date of first dose up to end of treatment (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)

  6. Duration of Remission (DoR)

    DoR: duration of CRc, CR, CRi, CRp \& response (CRc + PR). Duration of CRc/CR/CRi/CRp: time from date of first CRc/CR/CRi/CRp until date of documented relapse for participants who achieved CRc/CR/CRi/CRp. Duration of response: time from date of either first CRc or PR until date of documented relapse of any type for participants who achieved CRc or PR. CRc, CR, CRi, CRp were described in outcome measure #2 \& PR was described in outcome measure #6. Relapse after CR, CRp or CRi: reappearance of leukemic blasts in peripheral blood or ≥ 5% blasts in bone marrow aspirate/biopsy not attributable to any other cause or reappearance or new appearance of extramedullary leukemia. Relapse after PR: reappearance of significant numbers of peripheral blasts \& an increase in the percentage of blasts in the bone marrow aspirate/biopsy to \> 25% not attributable to any other cause or reappearance or new appearance of extramedullary leukemia. Analysis was performed using Kaplan-Meier estimates.

    Time frame: From date of first response until the date of documented relapse (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)

  7. Event Free Survival (EFS)

    EFS was defined as time from date of first dose until date of documented relapse from CR, CRp or CRi, treatment failure or death from any cause, whichever occurred first. CRc, CR, CRi, CRp were described in Outcome measure #2. For a participant with none of these events, EFS was censored at date of last disease assessment. Relapse after CR, CRp or CRi was defined as reappearance of leukemic blasts in peripheral blood or ≥ 5% blasts in bone marrow aspirate/biopsy not attributable to any other cause or reappearance or new appearance of extramedullary leukemia. Relapse after PR was defined with reappearance of significant numbers of peripheral blasts \& an increase in the percentage of blasts in the bone marrow aspirate/biopsy to \> 25% not attributable to any other cause or reappearance or new appearance of extramedullary leukemia. Treatment failure was defined as lack of CR, CRp or CRi, \& was determined at the end of treatment (EoT). Analysis was performed using Kaplan-Meier estimates.

    Time frame: From the date of first dose until the date of documented relapse from CR, CRp or CRi, treatment failure or death from any cause, whichever occurred first (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)

  8. Overall Survival (OS)

    OS was defined as the time from the date of first dose until the date of death from any cause. For a participant who was not known to have died by the end of study follow-up, overall survival was censored at the date of last contact. Analysis was performed using Kaplan-Meier estimates.

    Time frame: From the date of first dose until the date of death from any cause (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)

  9. Number of Participants With Treatment-Emergent Adverse Events

    An AE was any untoward medical occurrence in a participant administered study drug, \& which did not necessarily have to have a causal relationship with this treatment. Abnormalities was defined as AE only if met 1 of the criteria:Induced clinical signs/symptoms, required active intervention, required interruption or discontinuation of ST, abnormality or investigational value was clinically significant. Serious AE:resulted in death, was life threatening, persistent or significant disability/incapacity or substantial disruption of ability to conduct normal life functions, congenital anomaly/birth defect, required hospitalization or prolongation of hospitalization, other medically important events. Any AE recorded on treatment including within 30 days from last study treatment was classified as treatment-emergent AE (TEAE). Grades(Gr) based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE) (Gr 1=mild, Gr 2=moderate, Gr 3 =severe, Gr 4 =life threatening, Gr 5 =death).

    Time frame: Baseline to 30 days after last study treatment (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)

  10. Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Score

    ECOG performance status was measured on an 6 point scale. 0-Fully active, able to carry on all pre-disease performance without restriction. 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. 3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5. Dead.

    Time frame: Baseline and end of treatment (EoT) (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)

07

Results

Posted Jun 24, 2022

Participant flow

Study was planned for two phases, dose-escalation (phase 1) and dose expansion (phase 2). Sponsor decided not to open the phase 2 extension part of the study after completion of phase 1 dose escalation part.

Participant flow — Overall Study
MilestoneGilteritinib 120 mg + Atezolizumab 420 mgGilteritinib 120 mg + Atezolizumab 840 mg
Started38
Completed00
Not completed38
Withdrew: Adverse event01
Withdrew: Lack of efficacy15
Withdrew: Withdrawal by subject01
Withdrew: Miscellaneous21

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities (DLT)

DLTs were defined as: * Confirmed Hy's Law case * Any Grade ≥ 3 non-hematologic or extramedullary toxicity with the following exceptions: * Anorexia or fatigue * Grade 3 nausea and/or vomiting if participant did not require tube feeding or total parenteral nutrition, or diarrhea if the events did not require or prolong hospitalization that could be managed to grade ≤ 2 with standard antiemetic or antidiarrheal medications used at prescribed dose within 7 days of onset. * Grade 3 mucositis that resolved to Grade ≤ 2 within 7 days of onset * Grade 3 fever with neutropenia, with or without infection * Grade 3 infection * Grade 3 infusion-related toxicity, if successfully managed and resolved within 72 hours.

Time frame:
Day 1 up to 28 days
Reported as:
Number · Participants
Number of Participants With Dose Limiting Toxicities (DLT)
ParticipantsGilteritinib 120 mg + Atezolizumab 420 mgGilteritinib 120 mg + Atezolizumab 840 mg
Number of Participants With Dose Limiting Toxicities (DLT)02
SecondaryComposite Complete Remission (CRc) Rate

CRc was defined as rate of all complete and incomplete remissions i.e. CR + CR with incomplete platelet recovery (CRp) + CR with incomplete hematological recover (CRi). Participants were classified as: CR if they achieved morphologic leukemia-free state \& their bone marrow was regenerating normal hematopoietic cells. If they had absolute neutrophil count (ANC) \> 1 × 10\^9/L, platelet count ≥ 100 × 10\^9/L, normal marrow differential \< 5% blasts, \& were red blood cell (RBC) and platelet transfusion independent (defined as 1 week without RBC transfusion and platelet transfusion prior to disease assessment). There was also no evidence of extramedullary leukemia. CRp if they achieved CR with incomplete platelet recovery (\< 100 × 10\^9/L). CRi if they achieved CR with incomplete hematological recovery with residual neutropenia \< 1 × 10\^9/L, with or without complete platelet recovery. RBC and platelet transfusion independence was not required. Percentage of participants with CRc was reported.

Time frame:
From the date of first dose up to end of treatment (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)
Reported as:
Number · Percentage of participants
Composite Complete Remission (CRc) Rate
Percentage of participantsGilteritinib 120 mg + Atezolizumab 420 mgGilteritinib 120 mg + Atezolizumab 840 mg
Composite Complete Remission (CRc) Rate33.3 (0.8 to 90.6)12.5 (0.3 to 52.7)
SecondaryPlasma Ctrough Concentration of Gilteritinib

Plasma Ctrough concentrations of gilteritinib was reported. One cycle = 28 days. C= cycle, D=day

Time frame:
Pre-dose on C1D1, C1D8, C1D15, C2D1,C2D15, C3D1, C3D15, C4D1, C4D15, C5D1, C5D15, C6D1, C6D15
Reported as:
Mean · Nanogram per milliliter
Plasma Ctrough Concentration of Gilteritinib
Nanogram per milliliterGilteritinib 120 mg + Atezolizumab 420 mgGilteritinib 120 mg + Atezolizumab 840 mg
Pre-dose C1D1NA ± NANA ± NA
Pre-dose C1D8355 ± 240302 ± 155
Pre-dose C1D15483 ± 272553 ± 436
Pre-dose C2D1228422 ± 328
Pre-dose C2D15—83.3
Pre-dose C3D1—62.1
Pre-dose C3D15—75.2
SecondaryComplete Remission (CR) Rate

Participants were classified as CR if they achieved a morphologic leukemia-free state and their bone marrow was regenerating normal hematopoietic cells. In addition, these participants had ANC \> 1 × 10\^9/L, platelet count ≥ 100 × 10\^9/L, normal marrow differential with \< 5% blasts, and were RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion prior to disease assessment). There was also no evidence of extramedullary leukemia. CR rate was defined as the number of participants with CR divided by the number of participants in the analysis population. Percentage of participants with CR was reported.

Time frame:
From the date of first dose up to end of treatment (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)
Reported as:
Number · Percentage of participants
Complete Remission (CR) Rate
Percentage of participantsGilteritinib 120 mg + Atezolizumab 420 mgGilteritinib 120 mg + Atezolizumab 840 mg
Complete Remission (CR) Rate33.3 (0.8 to 90.6)0 (0 to 0)
SecondaryComplete Remission With Partial Hematologic Recovery (CRh) Rate

Participants were classified as CRh if they achieved CR with ANC level of \> 0.5 × 10\^9/L and platelet count of \> 50 × 10\^9/L. CRh rate was defined as the number of participants with CRh divided by the number of participants in the analysis population. Participants were classified as CR if they achieved a morphologic leukemia-free state and their bone marrow was regenerating normal hematopoietic cells. In addition, these participants had ANC \> 1 × 10\^9/L, platelet count ≥ 100 × 10\^9/L, normal marrow differential with \< 5% blasts, and were RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion prior to disease assessment). There was also no evidence of extramedullary leukemia. Percentage of participants with CRh was reported.

Time frame:
From the date of first dose up to end of treatment (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)
Reported as:
Number · Percentage of participants
Complete Remission With Partial Hematologic Recovery (CRh) Rate
Percentage of participantsGilteritinib 120 mg + Atezolizumab 420 mgGilteritinib 120 mg + Atezolizumab 840 mg
Complete Remission With Partial Hematologic Recovery (CRh) Rate0 (0 to 0)0 (0 to 0)
SecondaryBest Response Rate

Best response was defined as the best-measured response (CR, CRp, CRi or PR) post-treatment. Best response rate was defined as the number of participants with CR or CRp or CRi or PR divided by the number of participants in the analysis population (i.e., CR+ CRp + CRi + PR). Participants with unknown or missing response, or who provide no information on response at the end of study will be treated as non-responders and will be included in the denominator when calculating rates. CR, CRp and CRi were described in outcome measure 2#. Participants were classified as PR if their bone marrow was regenerating normal hematopoietic cells with evidence of peripheral recovery with no (or only a few regenerating) circulating blasts and a decrease of at least 50% in the percentage of blasts in the bone marrow aspirate/biopsy, with the total marrow blasts between 5% and 25%. Percentage of participants with best response was reported.

Time frame:
From the date of first dose up to end of treatment (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)
Reported as:
Number · Percentage of participants
Best Response Rate
Percentage of participantsGilteritinib 120 mg + Atezolizumab 420 mgGilteritinib 120 mg + Atezolizumab 840 mg
Best Response Rate33.3 (0.8 to 90.6)25 (3.2 to 65.1)
SecondaryDuration of Remission (DoR)

DoR: duration of CRc, CR, CRi, CRp \& response (CRc + PR). Duration of CRc/CR/CRi/CRp: time from date of first CRc/CR/CRi/CRp until date of documented relapse for participants who achieved CRc/CR/CRi/CRp. Duration of response: time from date of either first CRc or PR until date of documented relapse of any type for participants who achieved CRc or PR. CRc, CR, CRi, CRp were described in outcome measure #2 \& PR was described in outcome measure #6. Relapse after CR, CRp or CRi: reappearance of leukemic blasts in peripheral blood or ≥ 5% blasts in bone marrow aspirate/biopsy not attributable to any other cause or reappearance or new appearance of extramedullary leukemia. Relapse after PR: reappearance of significant numbers of peripheral blasts \& an increase in the percentage of blasts in the bone marrow aspirate/biopsy to \> 25% not attributable to any other cause or reappearance or new appearance of extramedullary leukemia. Analysis was performed using Kaplan-Meier estimates.

Time frame:
From date of first response until the date of documented relapse (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)
Reported as:
Median · Days
Duration of Remission (DoR)
DaysGilteritinib 120 mg + Atezolizumab 420 mgGilteritinib 120 mg + Atezolizumab 840 mg
Duration of Remission (DoR)NA (NA to NA)NA (31.0 to NA)
SecondaryEvent Free Survival (EFS)

EFS was defined as time from date of first dose until date of documented relapse from CR, CRp or CRi, treatment failure or death from any cause, whichever occurred first. CRc, CR, CRi, CRp were described in Outcome measure #2. For a participant with none of these events, EFS was censored at date of last disease assessment. Relapse after CR, CRp or CRi was defined as reappearance of leukemic blasts in peripheral blood or ≥ 5% blasts in bone marrow aspirate/biopsy not attributable to any other cause or reappearance or new appearance of extramedullary leukemia. Relapse after PR was defined with reappearance of significant numbers of peripheral blasts \& an increase in the percentage of blasts in the bone marrow aspirate/biopsy to \> 25% not attributable to any other cause or reappearance or new appearance of extramedullary leukemia. Treatment failure was defined as lack of CR, CRp or CRi, \& was determined at the end of treatment (EoT). Analysis was performed using Kaplan-Meier estimates.

Time frame:
From the date of first dose until the date of documented relapse from CR, CRp or CRi, treatment failure or death from any cause, whichever occurred first (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)
Reported as:
Median · Days
Event Free Survival (EFS)
DaysGilteritinib 120 mg + Atezolizumab 420 mgGilteritinib 120 mg + Atezolizumab 840 mg
Event Free Survival (EFS)175.00 (71.00 to NA)52.50 (2.00 to 58.00)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of first dose until the date of death from any cause. For a participant who was not known to have died by the end of study follow-up, overall survival was censored at the date of last contact. Analysis was performed using Kaplan-Meier estimates.

Time frame:
From the date of first dose until the date of death from any cause (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)
Reported as:
Median · Days
Overall Survival (OS)
DaysGilteritinib 120 mg + Atezolizumab 840 mgGilteritinib 120 mg + Atezolizumab 420 mg
Overall Survival (OS)175.00 (111.00 to NA)NA (51.00 to NA)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events

An AE was any untoward medical occurrence in a participant administered study drug, \& which did not necessarily have to have a causal relationship with this treatment. Abnormalities was defined as AE only if met 1 of the criteria:Induced clinical signs/symptoms, required active intervention, required interruption or discontinuation of ST, abnormality or investigational value was clinically significant. Serious AE:resulted in death, was life threatening, persistent or significant disability/incapacity or substantial disruption of ability to conduct normal life functions, congenital anomaly/birth defect, required hospitalization or prolongation of hospitalization, other medically important events. Any AE recorded on treatment including within 30 days from last study treatment was classified as treatment-emergent AE (TEAE). Grades(Gr) based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE) (Gr 1=mild, Gr 2=moderate, Gr 3 =severe, Gr 4 =life threatening, Gr 5 =death).

Time frame:
Baseline to 30 days after last study treatment (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent Adverse Events
ParticipantsGilteritinib 120 mg + Atezolizumab 420 mgGilteritinib 120 mg + Atezolizumab 840 mg
TEAE38
Drug-Related Adverse Events37
TEAE leading to Deaths12
Drug-related TEAE Leading to Deaths00
Serious Adverse Events37
Drug-Related Serious Adverse Events36
Adverse Events Leading to Withdrawal of Treatment26
Drug-Related Adverse Events Leading to Withdrawal of Treatment15
Grade 3 or Higher TEAE38
Treatment Emergent Deaths12
SecondaryNumber of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Score

ECOG performance status was measured on an 6 point scale. 0-Fully active, able to carry on all pre-disease performance without restriction. 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. 3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5. Dead.

Time frame:
Baseline and end of treatment (EoT) (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab)
Reported as:
Number · Participants
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Score
ParticipantsGilteritinib 120 mg + Atezolizumab 420 mgGilteritinib 120 mg + Atezolizumab 840 mg
Baseline: Grade 003
Baseline: Grade 134
Baseline: Grade 201
Baseline: Grade 300
Baseline: Grade 400
Baseline: Grade 500
EoT: Grade 001
EoT: Grade 111
EoT: Grade 201
EoT: Grade 311
EoT: Grade 400
EoT: Grade 500

Adverse events

Collected over Baseline to 30 days after last study treatment (Maximum treatment duration was 535 days for giltertinib and 112 days for atezolizumab). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gilteritinib 120 mg + Atezolizumab 420 mg2/3 (66.7%)3/3 (100%)3/3 (100%)
Gilteritinib 120 mg + Atezolizumab 840 mg4/8 (50%)7/8 (87.5%)8/8 (100%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventGilteritinib 120 mg + Atezolizumab 420 mgGilteritinib 120 mg + Atezolizumab 840 mg
Febrile neutropeniaBlood and lymphatic system disorders3/35/8
DeliriumPsychiatric disorders2/30/8
PyrexiaGeneral disorders0/33/8
HepatitisHepatobiliary disorders1/30/8
BacteraemiaInfections and infestations1/30/8
SepsisInfections and infestations1/30/8
Infusion related reactionInjury, poisoning and procedural complications1/30/8
Subdural haematomaInjury, poisoning and procedural complications1/30/8
Aspartate aminotransferase increasedInvestigations1/30/8
HyperuricaemiaMetabolism and nutrition disorders1/30/8
Most frequent other events
Showing 10 of 122
Most frequent other events
EventGilteritinib 120 mg + Atezolizumab 420 mgGilteritinib 120 mg + Atezolizumab 840 mg
Decreased appetiteMetabolism and nutrition disorders3/32/8
Muscular weaknessMusculoskeletal and connective tissue disorders3/31/8
DizzinessNervous system disorders3/31/8
DyspnoeaRespiratory, thoracic and mediastinal disorders3/33/8
Abdominal painGastrointestinal disorders2/30/8
ConstipationGastrointestinal disorders2/32/8
FatigueGeneral disorders2/34/8
Oedema peripheralGeneral disorders2/32/8
ContusionInjury, poisoning and procedural complications2/31/8
Weight decreasedInvestigations2/31/8

Baseline characteristics

The safety analysis set consisted of all participants who took at least 1 dose of study drug (gilteritinib or atezolizumab).

Age, Continuous
Age, Continuous(years)Gilteritinib 120 mg + Atezolizumab 420 mgGilteritinib 120 mg + Atezolizumab 840 mgTotal
Mean78 ± 8.764.8 ± 20.868.4 ± 18.9
Sex: Female, Male
Sex: Female, Male(Participants)Gilteritinib 120 mg + Atezolizumab 420 mgGilteritinib 120 mg + Atezolizumab 840 mgTotal
Female134
Male257
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Gilteritinib 120 mg + Atezolizumab 420 mgGilteritinib 120 mg + Atezolizumab 840 mgTotal
Hispanic or Latino000
Not Hispanic or Latino3811
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Gilteritinib 120 mg + Atezolizumab 420 mgGilteritinib 120 mg + Atezolizumab 840 mgTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American022
White369
More than one race000
Unknown or Not Reported000
08

Study locations

12 sites
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095, United States
  • University of Chicago
    Chicago, Illinois 60037, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Roswell Park Cancer Institute (RPCI)
    Buffalo, New York 14263, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • The Ohio State University Comprehensive Cancer Center (OSUCCC)
    Columbus, Ohio 43210, United States
  • Vanderbilt Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • Simmons Comprehensive Cancer Center
    Dallas, Texas 75390, United States
  • University of Texas MD Anderson
    Houston, Texas 77030, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in May 2021, 22 months.

Results were first posted in Jun 2022, 1 year 1 month after primary completion.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's 22 months is below that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2018
First posted
Nov 5, 2018
StartActual
Jun 19, 2019
Primary completionActual
May 14, 2021
CompletionActual
Jun 15, 2021
Results first posted
Jun 24, 2022
Last update
Nov 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03730012
Responsible party
Sponsor
First posted
Nov 5, 2018
Start date
Jun 19, 2019
Primary completion
May 14, 2021
Completion
Jun 15, 2021
Results posted
Jun 24, 2022
Last update
Nov 29, 2024

Study contacts

Executive Medical Director
study director · Astellas Pharma Global Development

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gilteritinib · Atezolizumab

Start the discussion